Cure8 research brief
Misdiagnosing GI tuberculosis as Crohn’s disease can lead to harmful immunosuppression and disseminated infection; conversely, missing IBD may delay appropriate therapy. Patients in TB-endemic areas face particular diagnostic uncertainty that can change treatment choices.
Clinicians (gastroenterologists, infectious disease physicians, primary care providers) working in TB-endemic or resource-limited settings; adult patients with suspected IBD or atypical colitis; caregivers and diagnosticians.
The article highlights the diagnostic overlap between colonic TB and IBD in TB-endemic, resource-limited settings. Endoscopic biopsies may miss submucosal granulomas, so deeper sampling and multiple modalities (radiology, cytology, molecular/culture testing) are important before starting immunosuppression.
The authors recommend pretreatment TB screening and a strictly time-limited empirical anti-TB trial when needed, with objective re-evaluation (including repeat endoscopy and biopsy) at around 8 weeks. This report does not provide generalizable outcome data — it is a single-case report emphasizing diagnostic caution rather than treatment efficacy evidence.
It is grounded in the article’s abstract and case description.
This is a single case report from a TB-endemic setting; recommendations reflect the authors’ experience and review rather than results from controlled studies. The extracted content is from the article abstract (structured content depth: abstract).
Review the original publication for the complete reporting, methods, and context.
Conflict statement: The authors declare no conflicts of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Because intestinal lymphoma can closely mimic Crohn’s disease, recognizing red flags (severe malabsorption, proximal small-bowel involvement, monoclonal gammopathy, poor response to IBD therapy) can change diagnosis and...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
A simple blood test (CRP) that's already used in IBD care might help predict which Crohn's patients with C. difficile coinfection are more likely to need intestinal surgery, enabling earlier attention or monitoring.
